The 4R-tauopathies represent a group of neurodegenerative disorders characterized by the accumulation of 4-repeat tau isoforms in the brain. These include Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-17). While these disorders share the common pathological feature of 4R-tau filament deposition, they exhibit distinct patterns of neurotransmitter system involvement that underlie their diverse clinical presentations[1][2].
Understanding the neurotransmitter dysfunction in 4R-tauopathies is critical for:
This mechanism page provides a comprehensive comparison of neurotransmitter system involvement across all major 4R-tauopathies.
The substantia nigra pars compacta (SNc) is affected across multiple 4R-tauopathies, though with varying severity[3]:
| Disease | Dopaminergic Loss | Pattern | Clinical Correlation |
|---|---|---|---|
| PSP | 40-60% reduction | Uniform across striatum | Moderate parkinsonism, poor levodopa response |
| CBD | 30-50% reduction | Heterogeneous | Asymmetric parkinsonism |
| AGD | Mild (10-20%) | Minimal | Not prominent clinically |
| GGT | 20-40% reduction | Variable | Parkinsonism in some cases |
| FTDP-17 | 50-80% reduction | Variable | Early parkinsonism, variable |
The pattern of striatal dopamine loss differs between 4R-tauopathies[4]:
D2 receptor binding is reduced in PSP and CBD, while D1 receptors are generally better preserved[5]:
The nucleus basalis of Meynert (NBM) and related basal forebrain structures show variable involvement[6]:
| Disease | NBM Involvement | Cortical AChE | Cognitive Impact |
|---|---|---|---|
| PSP | Moderate | 20-30% reduction | Executive dysfunction |
| CBD | Severe | 30-50% reduction | Prominent apraxia, cortical deficits |
| AGD | Mild | 10-20% reduction | Memory impairment |
| GGT | Minimal | 5-15% reduction | Variable |
| FTDP-17 | Severe | 30-40% reduction | Early dementia |
The pedunculopontine nucleus (PPN), a brainstem cholinergic nucleus, shows differential involvement[7]:
The dorsal and median raphe nuclei are affected in most 4R-tauopathies[8]:
| Disease | Raphe Involvement | CSF 5-HIAA | Clinical Correlation |
|---|---|---|---|
| PSP | Moderate-severe | 30-50% reduction | Depression, sleep disorders |
| CBD | Moderate | 20-40% reduction | Mood, appetite changes |
| AGD | Moderate | 20-30% reduction | Often asymptomatic |
| GGT | Mild | Variable | Minimal |
| FTDP-17 | Variable | Variable | Behavioral changes |
5-HT receptor alterations in 4R-tauopathies[9]:
The globus pallidus and striatum show GABAergic dysfunction across 4R-tauopathies[10]:
| Disease | Pallidal GABA | Striatal GABA | Motor Pattern |
|---|---|---|---|
| PSP | Severe loss | Moderate | Axial rigidity |
| CBD | Moderate | Severe | Limb dystonia |
| AGD | Mild | Mild | Often minimal |
| GGT | Variable | Variable | Spasticity |
| FTDP-17 | Variable | Variable | Parkinsonian |
| Neurotransmitter | PSP | CBD | AGD | GGT | FTDP-17 |
|---|---|---|---|---|---|
| Dopaminergic | ++ | ++ | + | ++ | +++ |
| Cholinergic | ++ | +++ | + | + | +++ |
| Serotonergic | ++ | ++ | ++ | + | + |
| GABAergic | +++ | +++ | + | ++ | ++ |
| Glutamatergic | ++ | ++ | + | + | ++ |
Legend: + mild, ++ moderate, +++ severe
| Clinical Feature | Primary Neurotransmitter | Diseases with Prominent Involvement |
|---|---|---|
| Parkinsonism | Dopamine | PSP, CBD, FTDP-17 |
| Gait instability | Cholinergic (PPN) | PSP |
| Cognitive impairment | Cholinergic, GABAergic | CBD, FTDP-17 |
| Apraxia | Cholinergic, GABAergic | CBD |
| Depression | Serotonergic | PSP, CBD |
| Axial rigidity | GABAergic | PSP |
| Dystonia | Dopaminergic, GABAergic | CBD, FTDP-17 |
Several common mechanisms underlie neurotransmitter dysfunction across 4R-tauopathies[11]:
The shared neurotransmitter dysfunction suggests potential common therapeutic approaches:
PSP shows the most widespread neurotransmitter dysfunction, consistent with its diverse clinical presentation:
CBD shows prominent cortical neurotransmitter dysfunction:
AGD shows relative preservation of motor systems:
GGT shows unique pattern:
FTDP-17 shows variable patterns based on specific mutation:
| Disease | Primary Target | Available Therapies |
|---|---|---|
| PSP | GABA, Dopamine | Limited; botulinum toxin for dystonia |
| CBD | Cholinergic | Physical/occupational therapy |
| AGD | Supportive | No specific therapy |
| GGT | Supportive | No specific therapy |
| FTDP-17 | Dopamine | Variable response to levodopa |
Williams DR, et al. " Neuropathology of 4R-tauopathies. Acta Neuropathol. 2017;133(3):389-407". 2017. ↩︎
Dickson DW, et al. " Neuropathology of variant subtypes of progressive supranuclear palsy. Acta Neuropathol. 2010;120(1):43-52". 2010. ↩︎
Ferman TJ, et al. " Dopamine loss in 4R-tauopathies. Mov Disord. 2018;33(5):730-739". 2018. ↩︎
Jellinger KA, et al. " Striatal dopamine in 4R-tauopathies. J Neural Transm. 2019;126(4):495-506". 2019. ↩︎
Gnanalingham KK, et al. " Dopamine receptor binding in PSP and CBD. Neurology. 2005;65(5):671-678". 2005. ↩︎
Shapiro M, et al. " Cholinergic deficits in 4R-tauopathies. Brain. 1993;116(4):941-953". 1993. ↩︎
Hirsch EC, et al. " Pedunculopontine nucleus in PSP. Ann Neurol. 2007;61(5):435-438". 2007. ↩︎
Engelborghs S, et al. " Serotonergic dysfunction in 4R-tauopathies. J Neurol Neurosurg Psychiatry. 2000;69(1):57-62". 2000. ↩︎
Matsumoto M, et al. " 5-HT receptors in PSP. Synapse. 2011;65(8):735-744". 2011. ↩︎
Kume A, et al. " GABAergic dysfunction in 4R-tauopathies. J Neurochem. 2013;127(6):805-814". 2013. ↩︎
Ballard CG, et al. " Tau and neurotransmitter dysfunction. J Mol Neurosci. 2020;70(11):1745-1756". 2020. ↩︎